title: [The conservative treatment of early-stage benign prostatic hypertrophy].
abstract: After outlining the methods currently used in benign prostate hyperplasia (BPH) treatment, data defining some etiological aspects of the disease are briefly analyzed. Initial experience had with the treatment of early stage BPH using Permixon--a drug exerting effect on alpha-2 reductase--is described. The results in a series of twenty-seven patients presenting BPH are encouraging.
authors.forename: Kh
authors.initials: Kh
authors.lastname: Kumanov
authors.forename: V
authors.initials: V
authors.lastname: Stoianova
authors.forename: A
authors.initials: A
authors.lastname: Lilov
authors.forename: D
authors.initials: D
authors.lastname: Kaloianov
mesh_terms: D058891:5-alpha Reductase Inhibitors; D000726:Androgen Antagonists / Q000627:therapeutic use; D004341:Drug Evaluation; D006801:Humans; D008297:Male; D010936:Plant Extracts / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D028024:Serenoa
chemical_list: D058891:5-alpha Reductase Inhibitors; D000726:Androgen Antagonists; D010936:Plant Extracts; C040972:saw palmetto extract